Publication and Presentation Strategies

More than 20 years of experience in generating and presenting complex scientific data in many forms for different audiences and purposes. Examples of peer reviewed publications are listed below to demonstrate the breadth of topics:

Medical Device

  • Imran, K, Tintera, B, Morrison H.A, Tupik J.D., Nagai-Singer M.A, Ivester H., Council-Troche M, Edwards M, Coutermarsh-Ott S, Byron C, Clark-Deener S, Uh K, Lee K, Boulos P, Rowe C, Coviello C, Allen I.C. Improved Therapeutic Delivery Targeting Clinically Relevant Orthotopic Human Pancreatic Tumors Engrafted in Immunocompromised Pigs Using Ultrasound-Induced Cavitation: A Pilot Study. Pharmaceutics 2023, 15, 1585.

  • Masiero M, Boulos P, Crake C, Rowe C, Coviello C. Ultrasound-induced cavitation and passive acoustic mapping: SonoTran platform performance and short-term safety in a large-animal model. Ultrasound Med Biol. 2022 Aug;48(8):1681-1690 

  • Myers R, Grundy M, Rowe C, Coviello C, Erbs P, Foloppe J, Finn S, Jackson E, Balloul JM, Story C, Coussios C, Carlisle R. Ultrasound Mediated Cavitation Does Not Decrease the Activity of Small Molecule, Antibody and Viral based Medicines. Int J Nanomedicine. 2018 Jan 10;13:337-349.  

  • Myers R, Coveillo C, Erbs P, Rowe C, Kwan J, Crake C, Finn S, Jackson E, Balloul JM, Story C, Coussios C, Carlisle R. Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus. Mol. Ther. 2016, 24(9):1627-33. 

 Preclinical Model Characterisation

  • Kostrzewski T, Cornforth T, Snow SA, Ouro-Gnao L, Rowe C, Large, E.M. and Hughes, D.J. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol 2017, 23: 204-215. 

  • Heslop JA, Rowe C, et al. Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch Toxicol 2017, 91: 439-452. 

  • Rowe C, Gerrard DT, Jenkins R, Berry A, Durkin K, Sundstrom L, Goldring CE, Park BK, Kitteringham NR, Hanley KP, Hanley NA. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology 2013, 58 (2), 799-809. 

  • Rowe C, Jenkins R, Kitteringham N, Park BK, Goldring C. Analysis of the rat primary hepatocyte nuclear proteome through sub-cellular fractionation. JIOMICS 2012, 2(2), 94-105. 

  • Rowe C, Goldring CE, Kitteringham NR, Jenkins RE, Lane BS, Sanderson C, Elliott V, Platt V, Metcalfe P, Park BK. Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. J Proteome Res 2010, 9 (5), 2658-68. 

  • Hall AM, Ward FJ, Shen CR, Rowe C, Bowie L, Devine A, Urbaniak SJ, Elson CJ, Barker RN. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: effects on autoantibody and T-helper responses. Blood 2007, 110 (13), 4511-7.   

Toxicology

  • Bell C, Dankers A, Lauschke V, Sison-Young R, Jenkins R, Rowe C, Goldring C, Park BK, Regan S, Walker T,  Schofield C, Baze A, Foster A, Williams D, Van de Ven A,  van Houdt J, Lähteenmäki T, Snoeys J, Juhila S, Richert L, Ingelman-Sundberg M. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multi-center study. Toxicol Sci. 2018 Apr 1;162(2):655-666. 

  • Rowe C, Shaeri M, Large E, Cornforth T, Robinson A, Kostrzewski T, Sison-Young R, Goldring C, Park BK, Hughes D. Perfused Human Hepatocyte Microtissues Identify Reactive Metabolite-Forming and Mitochondria-Perturbing Hepatotoxins. Toxicol In Vitro. 2017 Sep 15;46:29-38. 

  • Eakins R, Walsh J, Randle L, Jenkins RE, Schuppe-Koistinen I, Rowe C, Starkey Lewis P, Vasieva O, Prats N, Brillant N et al.. Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome. Sci Rep 2015, 5: 16423. 

  • Shelton LM, Lister A, Walsh J, Jenkins RE, Wong MH, Rowe C, Ricci E, Ressel L, Fang Y, Demougin P, Vukojevic V, O'Neill PM, Goldring CE, Kitteringham NR, Park BK, Odermatt A, Copple IM. Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney Int. 2015, 88(6):1261-1273. 

  • Godoy P, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013, 87 (8), 1315-530.  

  • Pritchett J, Harvey E, Athwal V, Berry, A, Rowe C, Oakley F, Moles A, Mann  DA, Bobola, N, Sharrocks AD, Thomson BJ, Zaitoun AM, Irving WL, Guha IN, Hanley NA, Hanley KP. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012, 56 (3), 1108-16. 

  • Megherbi R, Kiorpelidou E, Foster B, Rowe C, Naisbitt DJ, Goldring CE, Park BK. Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicol Appl Pharmacol 2009, 238 (2), 120-32.  

  Stem Cells

  • Sison-Young RL, Kia R, Heslop J, Kelly L, Rowe C, Cross MJ, Kitteringham NR, Hanley N, Park BK, Goldring CE. Human pluripotent stem cells for modeling toxicity. Adv Pharmacol 2012, 63, 207-56. 

  • Heslop JA et al. Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med. 2015, 4(4):389-400. 

  • Baxter M, Withey S, Harrison S, Segeritz CP, Zhang F, Atkinson-Dell R, Rowe C, Gerrard DT, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. Journal of Hepatolgy 2015, 62(3):581-9. 

  • Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, Kitteringham NR, Goldring, CE, Hanley NA. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 2010, 5 (1), 4-22. 

 Clinical

  • Jones RP, Sutton P, Greensmith RM, Santoyo-Castelazo A, Carr DF, Jenkins R, Rowe C, Hamlett J, Park BK, Terlizzo M, O'Grady E, Ghaneh P, Fenwick SW, Malik HZ, Poston GJ, Kitteringham NR. Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study. Cancer Chemother Pharmacol. 2013, 72(2):359-68.